Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANISE-II anifrolumab trial in primary Sjögren's syndrome
2022-000609-28Phase 2Active
- Sponsor
- University Medical Center Groningen
- Start
- Apr 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in primary Sjögren's syndrome comparing Anifrolumab with Placebo (2 arms). Primary endpoint: CRESS response at week 24. Started Apr 2022; status: active.
02
Drugs
anifrolumab
03
Conditions
primary Sjögren's syndrome
Beyond the preview
Go deeper on 2022-000609-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000609-28.